Accessibility Menu
Genmab A/s logo

Genmab A/s(OTC) GNMSF

Market Cap$19.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+1,879%
5 Year-32%
1 Year+38%
1 Month+13%
$335.00
+4.69%
+15.00Today
Genmab A/s last closing stock price
MetricPriceDate
Last closeUSD 320.002026-08-18
Genmab A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.73%USD 311.512026-08-07
1 month+13.48%USD 282.002026-07-17
3 month+18.74%USD 269.502026-05-20
Year to date+1.91%USD 314.002025-12-31
1 year+37.75%USD 232.302025-08-15
3 year-11.36%USD 361.002023-08-18
5 year-32.45%USD 473.722021-08-19
Since inception+1,878.97%USD 16.172004-04-16

Genmab A/s Financials at a Glance

Market Cap

$19.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.11B

Net Income (TTM)

$781.94M

EPS (TTM)

$12.66

P/E Ratio

24.96

Dividend

$0.00

Beta (Volatility)

0.35 (Low)

Price

$335.00

Volume

40,040

Open

$335.00

Previous Close

$320.00

Daily Range

$335.00 - $335.00

52-Week Range

$232.34 - $352.00

Estimated Earnings Date

Nov 5, 2026

GNMSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genmab A/s

Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and various other diseases. The company has established a strong portfolio of products and a robust pipeline aimed at addressing significant medical needs.

Products and Services
  • DARZALEX (daratumumab) for multiple myeloma
  • Teprotumumab for thyroid eye disease
  • Ofatumumab for chronic lymphocytic leukemia and multiple sclerosis
Growth Outlook
  • Recent quarterly revenue reached $896 million, indicating strong market demand
  • Pipeline includes multiple promising candidates in various stages of development
  • Strategic collaborations with major firms enhance growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of $3.8 billion reflects consistent growth
  • Operating income margin of 24.7% demonstrates operational efficiency
  • Net income of $53 million in the latest quarter shows profitability
Genmab A/S is well-positioned in the biotechnology sector, leveraging its innovative antibody technology to develop treatments for serious diseases. The company's flagship products, such as DARZALEX, have gained significant traction in the market, contributing to robust revenue growth. The recent quarterly results highlight a strong financial performance, with a notable increase in revenue and a solid operating income margin. The growth outlook remains positive, supported by a diverse pipeline of therapeutic candidates and strategic partnerships with leading pharmaceutical companies. These collaborations not only enhance Genmab's research capabilities but also expand its market reach. With a focus on innovation and a commitment to addressing unmet medical needs, Genmab A/S presents a compelling opportunity for investors interested in the biotechnology sector.
AI Generated • Jul 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,119

CEO

Jan G. J. van de Winkel, PhD

Website

www.genmab.com

Headquarters

Copenhagen, CD 2500, DK

GNMSF Financials

Key Financial Metrics (TTM)

Gross Margin

39.92%

Operating Margin

13.81%

Net Income Margin

8.17%

Return on Equity

13.58%

Return on Capital

11.39%

Return on Assets

6.30%

Earnings Yield

4.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.70M

Volume

40.04K

Avg. Volume

944.508

Financials (TTM)

Gross Profit

$3.83B

Operating Income

$1.32B

EBITDA

$1.36B

Operating Cash Flow

$891.19M

Capital Expenditure

-$22.10M

Free Cash Flow

$869.09M

Cash & ST Invst.

$1.50B

Total Debt

$5.25B

Genmab A/s Performance Analysis

Genmab A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,049,135,24452.0%
20232023-12-31USD 2,390,322,51516.7%
20242024-12-31USD 3,121,756,72930.6%
20252025-12-31USD 3,720,000,00019.2%
Genmab A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3010.5%
Q42025-12-314.0%
Q12026-03-31-15.7%
Q22026-06-3026.3%
Genmab A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 11.6761.2%
20232023-12-31USD 9.58-17.9%
20242024-12-31USD 17.6083.7%
20252025-12-31USD 15.36-12.7%
Genmab A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3019.9%
Q42025-12-31-92.9%
Q12026-03-3180.4%
Q22026-06-30479.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.13B

+22.3%

Gross Profit

$1.05B

+20.9%

Gross Margin

92.73%

N/A

Market Cap

$19.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.31M

N/A

Employees

3,029

N/A

Net Income

$296.80M

-11.6%

EBITDA

$398.68M

-11.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.50B

-48.5%

Total Debt

$5.25B

+3440.2%

Accounts Receivable

$67.75M

-93.2%

Inventory

$17.94M

+37.6%

Long Term Debt

$4.94B

+3634.5%

Short Term Debt

$310.87M

+1837.6%

Return on Assets

6.30%

N/A

Return on Invested Capital

11.71%

N/A

Free Cash Flow

$47.83M

-8.0%

Operating Cash Flow

$49.80M

-19.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GMABGenmab A/S
$33.54-1.69%
SBMFFSino Biopharmaceutical Limited
$0.65+0.00%
IKTInhibikase Therapeutics, Inc.
$2.35-4.29%
MBXBFMicrobix Biosystems Inc.
$0.22-4.82%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.82+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.73-0.05%
SPCXSpace Exploration Technologies
$132.34-0.05%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About GNMSF

What is the current price of Genmab A/s?

Genmab A/s is trading at $335.00 per share.

What is the 52-week range for Genmab A/s?

Over the past 52 weeks, Genmab A/s has traded between $232.34 and $352.00.

How much debt does Genmab A/s have?

As of the most recent reporting period, Genmab A/s reported total debt of $5.27B.

How much cash does Genmab A/s have on hand?

Genmab A/s reported $1.50B in cash and cash equivalents in its most recent financial results.

What is Genmab A/s’s dividend yield?

Genmab A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services